• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sucampo Pharmaceuticals - Articles and news items


FDA grants fast track designation to Sucampo’s cobiprostone for oral mucositis

Industry news / 8 May 2015 / Victoria White

The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis.


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +